aibioCLNN Clene Inc.
Clene (CLNN) news
Top story · Oct 20, 2026 · SEC filing 8-K
Clene signs a material agreement
On October 15, 2026, the Company entered into a subaward amendment for the fourth year of the NIH Grant with NYU for up to $7.2 million during the period from September 1, 2026 to August 31, 2027 (the “Subaward”).
Latest Clene news
We have not published a story on Clene yet. When there is news, it will appear here.
Clene annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $200,000 | $342,000 |
| Research and development | $14.0 million | $20.1 million |
| Net income (loss) | -$26.2 million | -$39.4 million |
| Cash from operations | -$18.5 million | -$21.3 million |
| Cash and equivalents | $5.2 million | $12.2 million |
| Short-term investments | $0 |
Questions about Clene
What is the ticker symbol of Clene?
Clene Inc. trades under the ticker CLNN on NASDAQ.
Where is Clene listed?
Clene Inc. is listed on NASDAQ.
What is the SEC CIK of Clene?
The SEC Central Index Key (CIK) for Clene Inc. is 1822791. Its filings are on SEC EDGAR.
How many shares does Clene have outstanding?
12,848,513 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-14.
Which country or territory is Clene listed under?
Our directory records Clene Inc. under United States.
What does Clene do?
Our directory classifies Clene Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Clene?
The ISIN recorded for Clene Inc. is US1856342019.
Does aibio.space cover Clene?
aibio.space lists Clene Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Clene incorporated?
SEC records list its state or country of incorporation as DE.
What was Clene's revenue last year?
$200,000 for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Is Clene profitable?
Clene Inc. reported a net loss of $26.2 million for the fiscal year ended Dec 31, 2025, and used $18.5 million of cash in operations, per its annual report to the SEC.
How much does Clene spend on research and development?
$14.0 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Clene have?
$9.7 million in cash at Jun 30, 2026, per its 10-Q.
What is Clene's market cap?
We do not publish live share prices. In its annual report, Clene Inc. put the market value of shares held by non-affiliates (public float) at $40.4 million as of Jun 30, 2025.
Is Clene a smaller reporting company?
SEC records list Clene Inc.'s filer category as: Non-accelerated filer<br>Smaller reporting company.
Investor discussion: Clene
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Financings
Reported a financing. SEC Form 424B5. Source
- Financings
Reported a financing. SEC Form 424B5. Source
- Financings
Reported a financing. SEC Form 424B5. Source
- Financings
Reported a financing. SEC Form 424B5. Source
- Financings
Reported a financing. SEC Form 424B5. Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). Source
- Listings
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). Source
- Listings
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 2.02,3.01,9.01). Source
- Financings
Reported a financing. SEC Form 8-K (Items 1.01,9.01). Source
- Financings
Filed a final prospectus for a securities offering. SEC Form S-3. Source
- Distress
Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02,2.03,8.01,9.01). Source
- Financings
Set up an at-the-market program to sell shares over time. SEC Form 424B5. Source
Stock chart
SEC filings and registration
- SEC name
- Clene Inc.
- CIK
- 1822791
- Industry (SIC)
- Pharmaceutical Preparations (2834)
- US tickers
- CLNN (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- 6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY, UT, 84121
- Phone
- 801-676-9695
- Shares outstanding
- 12,848,513 as of 2026-08-11 (10-Q filed 2026-08-14)
- Former names
- Chelsea Worldwide Inc.
Recent filings
Listing details
- Company
- Clene Inc.
- Ticker
- CLNN
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- US1856342019
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction